Crinetics Pharmaceuticals, Inc. (CRNX)

NMS – Цена в реальном времени. Валюта: USD

36.91

+0.36 (0.98%)

При закрытии: May 12, 2026, 4:00 PM EDT

36.99

+0.08 (0.22%)

После закрытия: May 12, 2026, 5:25 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Crinetics Pharmaceuticals, Inc. (CRNX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Crinetics Pharmaceuticals, Inc. (CRNX)

Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More

Видео

No Data

Пресс-релизы

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Search stocks

Crinetics Pharmaceuticals, Inc. (CRNX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Crinetics Pharmaceuticals, Inc. (CRNX)

Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More

Видео

No Data

Пресс-релизы

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update